Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this ...

Rodriguez has filed a new measure that would allow patients suffering from severe illnesses to have individualized treatment options.

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and ...

As if hot flashes, mood swings, uncomfortable sex, and a host of other symptoms weren't enough to deal with, menopause is ...

Known as OLX75016, the candidate is an antisense RNAi oligonucleotide developed using OliX’s therapeutic ... rejected ...